ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
17.40
-0.50 (-2.79%)
Dec 20, 2024, 4:00 PM EST - Market closed
ADMA Biologics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 382.81 | 258.22 | 154.08 | 80.94 | 42.22 | 29.35 | Upgrade
|
| Revenue Growth (YoY) | 63.39% | 67.59% | 90.36% | 91.72% | 43.85% | 72.79% | Upgrade
|
| Cost of Revenue | 193.4 | 167.17 | 118.82 | 79.77 | 53.79 | 39.5 | Upgrade
|
| Gross Profit | 189.41 | 91.04 | 35.27 | 1.17 | -11.57 | -10.16 | Upgrade
|
| Selling, General & Admin | 69.3 | 62.59 | 70.3 | 55.19 | 39.22 | 28.08 | Upgrade
|
| Research & Development | 1.87 | 3.3 | 3.61 | 2.85 | 5.91 | 2.34 | Upgrade
|
| Operating Expenses | 71.71 | 66.61 | 74.63 | 58.75 | 45.84 | 31.27 | Upgrade
|
| Operating Income | 117.69 | 24.43 | -39.37 | -57.57 | -57.41 | -41.42 | Upgrade
|
| Interest Expense | -17.27 | -25.03 | -19.28 | -13.06 | -11.99 | -8.99 | Upgrade
|
| Interest & Investment Income | 2.11 | 1.62 | 0.05 | 0.04 | 0.29 | 0.8 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.21 | -0.29 | -0.64 | -0.25 | -0.13 | -0.23 | Upgrade
|
| EBT Excluding Unusual Items | 102.33 | 0.74 | -59.23 | -70.85 | -69.24 | -49.84 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | - | -7.5 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | - | 11.53 | Upgrade
|
| Asset Writedown | -2.1 | -2.1 | - | - | - | - | Upgrade
|
| Other Unusual Items | -26.87 | -26.87 | -6.67 | -0.8 | 0.99 | -9.96 | Upgrade
|
| Pretax Income | 73.36 | -28.24 | -65.9 | -71.65 | -75.75 | -48.28 | Upgrade
|
| Income Tax Expense | 5.22 | - | - | - | - | - | Upgrade
|
| Net Income | 68.13 | -28.24 | -65.9 | -71.65 | -75.75 | -48.28 | Upgrade
|
| Net Income to Common | 68.13 | -28.24 | -65.9 | -71.65 | -75.75 | -48.28 | Upgrade
|
| Shares Outstanding (Basic) | 230 | 224 | 198 | 140 | 86 | 54 | Upgrade
|
| Shares Outstanding (Diluted) | 238 | 224 | 198 | 140 | 86 | 54 | Upgrade
|
| Shares Change (YoY) | 8.99% | 13.19% | 41.77% | 62.03% | 58.51% | 20.27% | Upgrade
|
| EPS (Basic) | 0.30 | -0.13 | -0.33 | -0.51 | -0.88 | -0.89 | Upgrade
|
| EPS (Diluted) | 0.28 | -0.13 | -0.33 | -0.51 | -0.88 | -0.89 | Upgrade
|
| Free Cash Flow | 79.39 | 4.03 | -73.42 | -125.88 | -114.73 | -80.01 | Upgrade
|
| Free Cash Flow Per Share | 0.33 | 0.02 | -0.37 | -0.90 | -1.33 | -1.47 | Upgrade
|
| Gross Margin | 49.48% | 35.26% | 22.89% | 1.45% | -27.41% | -34.60% | Upgrade
|
| Operating Margin | 30.74% | 9.46% | -25.55% | -71.13% | -135.99% | -141.14% | Upgrade
|
| Profit Margin | 17.80% | -10.94% | -42.77% | -88.52% | -179.41% | -164.50% | Upgrade
|
| Free Cash Flow Margin | 20.74% | 1.56% | -47.65% | -155.52% | -271.74% | -272.60% | Upgrade
|
| EBITDA | 125.89 | 32.76 | -32.25 | -52.08 | -53.47 | -38.17 | Upgrade
|
| EBITDA Margin | 32.89% | 12.69% | -20.93% | -64.34% | -126.65% | -130.04% | Upgrade
|
| D&A For EBITDA | 8.2 | 8.32 | 7.11 | 5.5 | 3.94 | 3.26 | Upgrade
|
| EBIT | 117.69 | 24.43 | -39.37 | -57.57 | -57.41 | -41.42 | Upgrade
|
| EBIT Margin | 30.74% | 9.46% | -25.55% | -71.13% | -135.99% | -141.14% | Upgrade
|
| Revenue as Reported | - | - | - | - | 42.22 | 29.35 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.